BETA3 INTEGRIN PROMOTER ACTIVATION IN OSTEOCLASTOGENESIS

整联蛋白β 3基因在破骨细胞和破骨细胞生成过程中高度表达，而β 3启动子在骨髓巨噬细胞（破骨细胞前体）中几乎沉默。 这种高水平的整合素β 3基因表达是正常破骨细胞分化、形态学和骨吸收所必需的。 最近克隆和表征的小鼠整合素β 3基因启动子，我们将确定β 3整合素基因启动子DNA序列直接表达在破骨细胞生成。 此外，我们建议确定的转录因子，反式激活β 3整合素基因在破骨细胞。最近的革命性进展，在我们的理解细胞因子指导破骨细胞生成已经有可能诱导破骨细胞的形成从不朽的，重要的是，可转染的巨噬细胞系。 因此，有可能，第一次，研究破骨细胞的转录机制，通过转染巨噬细胞与破骨细胞特异性基因启动子/报告构建体，然后诱导破骨细胞生成。 启动子缺失和诱变，随后进行生物活性测定，将有助于确定重要的启动子序列，而体外和体内DNA足迹技术将确定与破骨细胞及其前体中的核蛋白相互作用的位点。 凝胶迁移试验（EMSA），启动子寡核苷酸序列，与控制共识转录因子结合位点寡核苷酸相比，将用于确定破骨细胞和前体核因子和β-3启动子DNA元件之间的体外结合相互作用。 此外，已知转录因子的抗体将用于"超移位"核蛋白/DNA复合物，从而鉴定移位复合物的组分。 然后在整个启动子的背景下突变核因子结合位点，并测定破骨细胞生成期间的转录激活。 虽然不是这个提议的具体目的，但上述实验对于鉴定新的破骨细胞特异性转录因子具有令人兴奋的潜力。β-3基因的破骨细胞转录机制可能被其他几个破骨细胞富集和破骨细胞特异性基因所共享。 因此，除了显着增加我们对指导破骨细胞分化的分子细胞事件的了解之外，破骨细胞转录机制的表征可能有助于识别抗破骨细胞生成疗法的新靶点。

The integrin beta3 gene is highly expressed in osteoclasts and during osteoclastogenesis yet the beta3 promoter is nearly silent in bone marrow macrophage, the osteoclast precursor. This high level of integrin beta3 gene expression is required for normal osteoclast differentiation, morphology, and bone resorption. Having recently cloned and characterized the mouse integrin beta3 gene promoter, we will determine which beta3 integrin gene promoter DNA sequences direct expression during osteoclastogenesis. In addition we propose to identify the transcription factors which trans-activate the beta3 integrin gene in osteoclastogenesis. Recent revolutionary advances in our understanding of the cytokine factors directing osteoclastogenesis have made it possible to induce osteoclast formation from immortal, and importantly, transfectable macrophage cell lines. It is therefore possible, for the first time, to study the transcription machinery of osteoclasts by transfection of macrophage with an osteoclast-specific gene promoter/reporter construct followed by induction of osteoclastogenesis. Promoter deletions and mutagenesis, followed by assays for biological activity, will help identify important promoter sequences, while in-vitro and in-vivo DNA footprinting techniques will identify sites of interaction with nuclear proteins in osteoclasts and their precursors. Gel-shift assays (EMSA), with promoter oligonucleotide sequences, compared with control consensus transcription factor binding site oligonucleotides, will be employed to identify in-vitro binding interactions between osteoclast and precursor nuclear factors and beta-3 promoter DNA elements. In addition, antibodies to known transcription factors will be used to "super-shift" the nuclear protein/DNA complexes, thereby identifying components of shifted complexes. Nuclear factor binding sites will then be mutated in the context of the entire promoter and assayed for transcriptional activation during osteoclastogenesis. While not the specific aim of this proposal, the experiments described above hold the exciting potential for the identification of novel osteoclast-specific transcription factors. The osteoclastic transcriptional machinery for the beta-3 gene is likely shared by several other osteoclast-enriched and osteoclast-specific genes. Therefore, in addition to significantly increasing our understanding of the molecular cellular events directing osteoclast differentiation, the characterization of osteoclast transcriptional machinery may help identify novel targets for anti-osteoclastogenic therapies.